2025-05-11 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Report

**0. Key Figures & Initial Analysis:**

UNH's cumulative return significantly lags behind the S&P 500 (VOO).  While UNH shows a 38.11% return, VOO boasts an 87.98% return, resulting in a substantial negative divergence.  Further analysis is needed to determine the underlying reasons for this underperformance.


**1. Performance Comparison & Alpha/Beta Analysis:**

UnitedHealth Group Inc. (UNH) is a diversified healthcare company offering a range of health benefit programs and related services.

The provided data shows a considerable underperformance of UNH compared to the S&P 500 (VOO) over the analyzed period.  The final cumulative return difference is -49.9%, placing it at the 0th percentile of its historical range of performance relative to the VOO.

The Alpha/Beta analysis reveals fluctuating performance. While Alpha (outperformance relative to the market) is generally positive, suggesting some degree of manager skill, it's inconsistent.  Beta (market sensitivity) varies, indicating changing levels of market risk exposure over time.  The CAGR (Compound Annual Growth Rate) also fluctuates significantly, highlighting the volatility of UNH's performance.  Note that the exceptionally large negative CAGR values in the later years need to be investigated and context provided.  Itâ€™s crucial to examine external factors during those periods that contributed to the negative performance.


**2. Recent Price Movement:**

* **Closing Price:** $385.55 (previous close) / $380.64 (last market price)  
* **5-Day Moving Average:** $395.17
* **20-Day Moving Average:** $457.21
* **60-Day Moving Average:** $487.21

The stock price is currently below all three moving averages, indicating a bearish short-term trend. The recent price drop of -$1.27 (-0.33%) should be considered within the context of broader market conditions and the recent earnings performance.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.37 (Medium Risk)
* **RSI:** 12.22 (Deeply oversold, suggesting potential bounce, though not a guarantee)
* **PPO:** -1.37 (Negative, confirming bearish momentum)
* **20-Day Relative Divergence Change:** 0.0 (Flat short-term relative divergence)
* **Expected Return:** 1216.2% (This figure needs clarification.  Is this an annualized return? What are the assumptions and risk factors underlying this projection?)

The low RSI suggests the stock might be oversold, potentially creating a buying opportunity. However, the negative PPO and the overall price trend suggest caution. The dramatically high expected return requires further justification and should be viewed with skepticism.


**4. Recent Earnings Analysis:**

| Date       | EPS      | Revenue        |
|------------|----------|-----------------|
| 2025-05-07 | $6.9     | $109.58 B      |
| 2024-11-04 | $6.56    | $100.82 B      |
| 2024-08-09 | $4.58    | $98.86 B       |
| 2024-05-09 | -$1.53   | $99.80 B       |
| 2024-05-07 | -$1.53   | $99.80 B       |

The earnings data shows significant volatility. The inclusion of two identical rows for 2024-05 requires clarification. The large negative EPS in Q2 2024 is a major concern and needs thorough investigation and explanation of the underlying causes. The subsequent strong EPS results might partially compensate, but overall the picture is uncertain.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2025-03-31 | $109.58B   | 21.70%        |
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |
| 2024-03-31 | $99.80B    | 23.05%        |


**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2025-03-31 | $95.04B    | 6.62%         |
| 2024-12-31 | $92.66B    | 5.98%         |
| 2024-09-30 | $94.53B    | 6.41%         |
| 2024-06-30 | $89.36B    | 4.72%         |
| 2024-03-31 | $86.69B    | -1.63%        |

Revenue shows consistent growth, but profitability (profit margin) fluctuates.  The negative ROE in Q1 2024 is concerning and needs further explanation. Overall, the financial data is generally positive, but the significant negative values in the recent past need closer examination.


**6. Overall Analysis:**

UNH shows a concerning underperformance compared to the S&P 500, despite generally positive financial figures.  The recent price decline, combined with a deeply oversold RSI, suggests a potential short-term bounce. However,  the negative PPO and the volatile earnings data, including a substantial negative EPS in one quarter, raise significant concerns.  The exceptionally high projected return requires much more rigorous analysis and justification.  Before considering any investment, a thorough investigation into the reasons behind the negative earnings and the significant underperformance against the market is crucial.  Additionally, the provided data lacks critical context; more information about macroeconomic factors, industry trends, and UNH's specific business strategies is necessary for a comprehensive assessment.
